Generic Name and Formulations:
Ceftazidime 1g, 2g; pwd for IM or IV inj, or IV infusion after reconstitution; sodium content 2.3mEq/g.
Indications for TAZICEF:
Susceptible infections including lower respiratory tract (eg, pneumonia), skin and skin structure, UTIs, septicemia, bone and joint, gynecologic (eg, endometritis, pelvic cellulitis), meningitis, intraabdominal (eg, peritonitis).
Administer in upper outer quadrant of the gluteus maximus or lateral part of the thigh. Usual dose: 1g IV or IM every 8–12 hours. Uncomplicated UTIs: 250mg IV or IM every 12 hours. Complicated UTIs: 500mg IV or IM every 8–12 hours. Bone and joint: 2g IV every 12 hours. Uncomplicated pneumonia, mild skin and skin structure: 500mg–1g IV or IM every 8 hours. Serious gynecologic, intraabdominal, meningitis, or very severe life threatening (eg, immunocompromised): 2g IV every 8 hours. Lung infections: 30–50mg/kg IV every 8 hours; max of 6g/day. Renal dysfunction: CrCl 31–50mL/min: 1g every 12 hours; CrCl 16–30mL/min: 1g every 24 hours; CrCl 6–15mL/min: 500mg every 24 hours; CrCl <5mL/min: 500mg every 48 hours. Hemodialysis: 1g loading dose then 1g after each dialysis session. Peritoneal dialysis: 1g loading dose then 500mg every 24 hours.
Neonates: 30mg/kg IV every 12 hours. 1 month-12 years: 30–50mg/kg IV every 8 hours, max of 6g/day. Renal impairment: reduce dose.
Penicillin or other allergy. Renal or hepatic impairment, poor nutritional state, long term use: monitor prothrombin time. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Nephrotoxicity with concomitant aminoglycosides, diuretics (eg, furosemide). Antagonized by chloramphenicol. False (+) glucose test with Clinitest, Benedict's, or Fehling's soln.
Hypersensitivity reactions (eg, rash, pruritus, fever), local reactions, GI upset, elevated liver enzymes.
Vials 1g—1, 10, 25
Clinical Pain Advisor Articles
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Pediatric Opioid Prescriptions Have Declined Since 2012
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- ACA Coverage Substantial, but Did Not Impact Labor Markets
- AMA to Collect Data on Suicide Among Doctors-in-Training
- Smartphone App Improves Management of Cancer-Related Pain, Anxiety